Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Regeneron: AcTED results posted; new REGN9220 and glaucoma trials registeredOct 23Weekly roundup, 4 itemsafliberceptcemiplimab-rwlcUpdated
Sign inSign in